Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01772420 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia
A Phase 2 study of Chronic Myelomonocytic Leukemia and Anemia, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 2
- Study locations
NCT01772420 is a Phase 2 study of Chronic Myelomonocytic Leukemia and Anemia that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 52 participants, below the 88-participant average among 73 other Chronic Myelomonocytic Leukemia trials with a reported enrollment target (41% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01772420, a Phase 2 study of Chronic Myelomonocytic Leukemia and Anemia, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies how well lenalidomide (LEN) and eltrombopag olamine (ELT) work in treating patients with symptomatic anemia in low or intermediate myelodysplastic syndrome (MDS). Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Eltrombopag olamine may increase the number of white blood cells and platelets found in bone marrow or peripheral blood. Giving lenalidomide and eltrombopag olamine may be an effective treatment for myelodysplastic syndrome.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Lenalidomide
- DRUG Eltrombopag Olamine
Study Locations (2)
Kansas
- University of Kansas Cancer Center - Kansas City
New York
- Albert Einstein College of Medicine - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2012-10 |
| Est. Completion | 2020-07-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01772420
The ClinicalTrials.gov registry entry for NCT01772420 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 88-participant average among 73 other Chronic Myelomonocytic Leukemia trials with a reported enrollment target (41% lower). The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Chronic Myelomonocytic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01772420 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Kansas, New York.
Frequently Asked Questions
What is clinical trial NCT01772420 about?
NCT01772420 is a clinical study titled "Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia". This phase II trial studies how well lenalidomide (LEN) and eltrombopag olamine (ELT) work in treating patients with symptomatic anemia in low or intermediate myelodysplastic syndrome (MDS). Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Eltrombopa...
What is the current status of trial NCT01772420?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2012-10. Estimated completion is 2020-07-09.
What conditions does trial NCT01772420 study?
This clinical trial studies the following conditions: Chronic Myelomonocytic Leukemia, Anemia, Adult Myelodysplastic Syndrome.
What interventions are being tested in trial NCT01772420?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Lenalidomide (DRUG), Eltrombopag Olamine (DRUG).
Who is sponsoring clinical trial NCT01772420?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01772420 being conducted?
This trial has 2 study locations across Kansas, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myelomonocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
RECRUITING · Phase 2
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
-
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
RECRUITING · Phase 2
-
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.